tbuckley/cabot-search huggingface dataset:
Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials
Authors: Pieter Hindryckx, Barrett G Levesque, Tom Holvoet, Serina Durand, Ceen-Ming Tang, Claire Parker, Reena Khanna, Lisa M Shackelton, Geert D'Haens, William J Sandborn, Brian G Feagan, Benjamin Lebwohl, Daniel A Leffler, Vipul Jairath
Journal: Gut (2016)

Objective Although several pharmacological agents have emerged as potential adjunctive therapies to a gluten-free diet for coeliac disease, there is currently no widely accepted measure of disease activity used in clinical trials. We conducted a systematic review of coeliac disease activity indices to evaluate their operating properties and potential as outcome measures in registration trials. Design MEDLINE, EMBASE and the Cochrane central library were searched from 1966 to 2015 for eligible studies in adult and/or paediatric patients with coeliac disease that included coeliac disease activity markers in their outcome measures. The operating characteristics of histological indices, patient-reported outcomes (PROs) and endoscopic indices were evaluated for content and construct validity, reliability, responsiveness and feasibility using guidelines proposed by the US Food and Drug Administration (FDA). Results Of 19 123 citations, 286 studies were eligible, including 24 randomised-controlled trials. Three of five PROs identified met most key evaluative criteria but only the Celiac Disease Symptom Diary (CDSD) and the Celiac Disease Patient-Reported Outcome (CeD PRO) have been approved by the FDA. All histological and endoscopic scores identified lacked content validity. Quantitative morphometric histological analysis had better reliability and responsiveness compared with qualitative scales. Endoscopic indices were infrequently used, and only one index demonstrated responsiveness to effective therapy. Conclusions Current best evidence suggests that the CDSD and the CeD PRO are appropriate for use in the definition of primary end points in coeliac disease registration trials. Morphometric histology should be included as a key secondary or co-primary end point. Further work is needed to optimise end point configuration to inform efficient drug development.
TCT-361 Targeting Transradial Approach: an Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Francesca Del Furia, Gennaro Giustino, Matteo Montorfano, francesco giannini, Mauro Carlino, Azeem Latib, Richard Jabbour, Luca Angelo Ferri, Susanna Benincasa, Alaide Chieffo, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
TCT-288 Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Intervention: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaborative Patient-Level Pooled Analysis
Authors: Gennaro Giustino, Usman Baber, Philippe Généreux, Gregg Stone, Martin Leon, George Dangas, Samantha Sartori, Melissa Aquino, Stephan Windecker, Patrick Serruys, Adnan Kastrati, William Wijns, Philippe Gabriel Steg, Giulio Stefanini, Marco Valgimigli, Takeshi Kimura, Clemens von Birgelen, Edoardo Camenzind, Soeren Galatius, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
TCT-757 Effect of Left Ventricular Ejection Fraction on Long-term Clinical Outcomes in Patients with Severe Aortic Stenosis
Authors: Tomohiko Taniguchi, Takeshi Morimoto, Hiroki Shiomi, Kenji Ando, Takeshi Kitai, Chisato Izumi, Naritatsu Saito, Ryuzo Sakata, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2016)
Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study
Authors: Samantha Pozzi, Stefania Badiali, Alessandro Corso, Pellegrino Musto, Attilio Guarini, Carla Minoia, Donatella Vincelli, Roberto Ria, Luciano Masini, Giovanni Quarta, Massimo Gentile, Carla Mazzone, Antonio Palumbo, Fortunato Morabito, Stefano Sacchi
Journal: Blood (2013)
Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care
Authors: Giovanni Sotgiu, Netta Beer, Stefano Aliberti, Giovanni Battista Migliori, Marieke J. van der Werf
Journal: European Respiratory Journal (2016)

Tuberculosis (TB) is one of the most important clinical and public health infectious disease threats globally [1]. Its burden is substantial, with annually ∼9.6 million incident cases and 1.5 million deaths worldwide [1]. Since 1990, the previous decreasing global annual incidence trend has reversed due to the emergence of HIV/AIDS and the increase in TB–HIV co-infection. In addition, multidrug-resistant TB (MDR-TB) has emerged as a problem [1]. This change in the epidemiology has significantly challenged the control of TB through the World Health Organization (WHO) DOTS (directly observed treatment, short course) strategy, and forced international and national public health authorities to design and plan new operational strategies. New European Union standards for TB care and prevention to achieve WHO target of TB elimination by 2050 in EU/EEA <http://ow.ly/NlhE302UXLV>
Predictive and prognostic functions of microtubule-associated protein-tau and topoisomerase IIα protein in early breast cancer
Authors: M. Choi, H. Won, K. Lee, S. Sung, B. Moon, H. Choi, H. Suh, E. Nam, S. Lee
Journal: Journal of Clinical Oncology (2009)

e22169 Background: Topoisomerase IIα protein(topo II) is the molecular target of topo II inhibitors such as anthracyclines and Microtubule-Associated Protein(MAP)-tau protein is associated with taxane sensitivity. Anthracyclins and taxanes are major cytotoxic agents of breast cancer in the adjuvant setting. The aim of this study was to evaluate the predictive and prognostic functions of MAP-tau and topo II in early breast cancers. Methods: Representative breast tumor sections were constructed from paraffin embedded specimens from 78 node positive breast cancer patients. MAP-tau and topo II protein were assessed by immunochemistry using antibody clone 4F1(Affinity BioReagents,USA) and clone Ki-S1 antibody(Dakocytomation,USA). MAP-tau staining of tumor cells was semiquantatively scored as 0, 1+, 2+, 3+ and cases with 0 or 1+ staining intensity were considered MAP-tau negative. Topo II protein over- expression was defined as the detection of nuclear staining in more than median value of evaluated cells. Results: Thirty- four cases (43.6%) of 78 samples showed topo II overexpression and 35 cases(44.9%) showed MAP-tau overexpression in node positive breast cancers. HER2 overexpression was noted in 28 samples (35.9%) and 56 cases (71.8%) were compatible with the luminal type. In 43 patients (55.1%), anthracyclin and taxane were used as adjuvant therapy and in this group, both MAP-tau and topo II overexpression showed lower disease-free survival (DFS) than the others, but statistically not significant. In luminal type, MAP-tau overexpression was poor prognostic factor on DFS in Cox regression.(HR 5.644, 95% CI 1.14–28.07, p=0.034) Conclusions: Topo II overexpression and MAP-tau overexpression in node positive breast cancers were not significant predictive factors for anthracyclin and taxane therapies. As several investigators reported, MAP-tau is associated endocrine therapy sensitivity in patients without chemotherapy, but higher MAP-tau in luminal type was a strong poor prognostic factor in patients who were given chemotherapy and hormonal therapy. No significant financial relationships to disclose.
Molecular Profiling of Extramedullary and Medullary Plasmacytomas
Authors: Gabriela Motyckova, Aliyah Rahemtullah, Nileshwari Vaghela, Sonia Vallet, Adam Ackerman, Siddhartha Mukherjee, Samantha Pozzi, Loredana Santo, Diana Cirstea, Christiana Toomey, Ephraim P. Hochberg, Paola Dal Cin, Scott Rodig, Teru Hideshima, Kenneth C Anderson, Nikhil Munshi, Noopur Raje
Journal: Blood (2008)
Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps
Authors: Jiun-Bo Chen, Louisa K. James, Anna M. Davies, Yu-Chang Bryan Wu, Joanne Rimmer, Valerie J. Lund, Jou-Han Chen, James M. McDonnell, Yih-Chih Chan, George H. Hutchins, Tse Wen Chang, Brian J. Sutton, Harsha H. Kariyawasam, Hannah J. Gould
Journal: Journal of Allergy and Clinical Immunology (2016)

Chronic rhinosinusitis with nasal polyps is associated with local immunoglobulin hyperproduction and the presence of IgE antibodies against Staphylococcus aureus enterotoxins (SAEs). Aspirin-exacerbated respiratory disease is a severe form of chronic rhinosinusitis with nasal polyps in which nearly all patients express anti-SAEs.We aimed to understand antibodies reactive to SAEs and determine whether they recognize SAEs through their complementarity-determining regions (CDRs) or framework regions.Labeled staphylococcal enterotoxin (SE) A, SED, and SEE were used to isolate single SAE-specific B cells from the nasal polyps of 3 patients with aspirin-exacerbated respiratory disease by using fluorescence-activated cell sorting. Recombinant antibodies with "matched" heavy and light chains were cloned as IgG1, and those of high affinity for specific SAEs, assayed by means of ELISA and surface plasmon resonance, were recloned as IgE and antigen-binding fragments. IgE activities were tested in basophil degranulation assays.Thirty-seven SAE-specific, IgG- or IgA-expressing B cells were isolated and yielded 6 anti-SAE clones, 2 each for SEA, SED, and SEE. Competition binding assays revealed that the anti-SEE antibodies recognize nonoverlapping epitopes in SEE. Unexpectedly, each anti-SEE mediated SEE-induced basophil degranulation, and IgG1 or antigen-binding fragments of each anti-SEE enhanced degranulation by the other anti-SEE.SEEs can activate basophils by simultaneously binding as antigens in the conventional manner to CDRs and as superantigens to framework regions of anti-SEE IgE in anti-SEE IgE-FcεRI complexes. Anti-SEE IgG1s can enhance the activity of anti-SEE IgEs as conventional antibodies through CDRs or simultaneously as conventional antibodies and as "superantibodies" through CDRs and framework regions to SEEs in SEE-anti-SEE IgE-FcεRI complexes.
Prevention of febrile neutropenia by prophylactic use of G-CSF with adjuvant TAC based on risk assessment—Single institute study
Authors: M. K. Chellama, S. A. Awadhi, V. Vyas, J. Nemec, A. Khodary, F. Enezi, M. D. Delvadiya
Journal: Journal of Clinical Oncology (2006)

10711 Background: TAC confers significant disease free and overall survival benefits vs FAC for patients with node positive breast cancer. However TAC is associated with higher incidence of febrile neutropenia. In our study prophylactic G-CSF was used in patients, who developed grade 4 neutropenia with ANC &lt; 100 or febrile neutropenia to prior cycle of TAC. Methods: Following surgery, patients with operable, 1–9 nodes positive breast cancer, ECOG 0–1, and adequate hematologic and organ function were enrolled on to the study, and were to receive TAC day 1 every 3 weeks for 6 cycles . All patients received prophylactic Ciprofloxacin 500-mg bid from days 5–14 after each cycle of chemotherapy unless prophylactic G-CSF was given. Eighty three patients were enrolled during the period 13–1-04 to 30–12–05. Patients who had received at least 2 cycles of TAC were eligible for evaluation. Patients were given prophylactic G-CSF if they had profound neutropenia (ANC &lt; 100) or febrile neutropenia in prior cycle. Results: At the cut-off date for this analysis 79 patients were evaluable. 68 patients had completed the planned 6 cycles of TAC. Three, 2, 3 and 3 patients completed 2, 3, 4 and 5 cycles respectively. Sixty one patients required prophylactic G-CSF - 21 after febrile neutropenia in prior cycle, 39 after profound neutropenia in prior cycle and 1 received from first cycle itself because of post operative seroma with diabetes mellitus. 23 patients developed febrile neutropenia (29.1%) - 3, 8, and 12 after 3, 2 and 1 cycles respectively. Only two patients (3.2%) who received prophylactic G-CSF developed febrile neutropenia. Full dose of TAC could be maintained in 98.6% cycles. Conclusions: The use of G-CSF prophylaxis based on risk assessment could prevent febrile neutropenia in patients, who had profound neutropenia in prior cycle. Also G-CSF could prevent further febrile neutropenia in patients who had developed the same in prior cycle. The above strategy helped in maintaining the dose intensity of TAC. No significant financial relationships to disclose.
Abstract 1059: Analysis of promoter methylation levels of COX2 gene in Turkish patients with head and neck cancer
Authors: Semra Demokan, Cansu Ozkoklesen, Zubeyde Yalniz, Necati Enver, Murat Ulusan, Nejat Dalay
Journal: Cancer Research (2015)

Abstract Purpose: Methylation of CpG islands in the promoter regions of genes plays an important role in head and neck carcinogenesis. Overexpression of COX2 gene was recorded in various types of cancer in literature. In addition, the promoter region of the COX2 gene displayed high methylation in normal colorectal tissue and normal gastric tissue samples. On the other hand, it has recently been reported in two different gastrointestinal cancer studies, that low expression of COX2 was observed in some colorectal/gastric cancers and hypermethylation/related transcriptional silencing of COX2 gene is common in colorectal cancer. There is no study investigating the COX2 methylation status on head and neck cancer (HNC) in the literature. In our study we evaluated the COX2 gene promoter methylation in patients with HNC. Experimental Design: Methylation of the COX2 was investigated by bisulfite modification/methylation-specific polymerase chain reaction in tumors and matched normal tissue samples from 99 Turkish patients with HNC. Results: The promoter region of the COX2 was methylated in 53.5% and 65.6% of the primary tumors and the corresponding normal tissue samples, respectively [p = 0.082, χ2 = 3.02, OR(95%CI) = 0.602 (0.34-1.06)]. Considering the methylation levels observed in our previous studies, and published data on different cancer types, methylation levels &amp;lt;10% were considered unmethylated, whereas levels between 10% to 25% and 25% to 100% were classified as moderate and high methylation, respectively. Based on this information, methylation ratio was observed less than 10% in 46.5% and 34.3% of tumor and normal samples, respectively. The moderate methylation levels (10-25%) were found in 23.2% of the tumors and 7.1% of the adjacent normal tissues. High methylation levels (&amp;gt;25%) were 30.3% and 58.6% in the tumor and normal tissues, respectively (p = 0.00006, χ2 = 19.24). The results were similar when a subgroup of 60 patients with larynx cancer from this cohort, were analyzed separately (p = 0.0006, χ2 = 14.87). Conclusions: Methylation may play an important role in HNC carcinogenesis. Although we found that there was no significant association between the methylation levels of tumor and adjacent normal tissues, high methylation levels of the COX2 gene were observed (&amp;gt;25%) in normal matched tissues when compared to the levels in HNC tumors. Citation Format: Semra Demokan, Cansu Ozkoklesen, Zubeyde Yalniz, Necati Enver, Murat Ulusan, Nejat Dalay. Analysis of promoter methylation levels of COX2 gene in Turkish patients with head and neck cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1059. doi:10.1158/1538-7445.AM2015-1059
Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality
Authors: Ruben N Eppinga, Yanick Hagemeijer, Stephen Burgess, David A Hinds, Kari Stefansson, Daniel F Gudbjartsson, Dirk J van Veldhuisen, Patricia B Munroe, Niek Verweij, Pim van der Harst
Journal: Nature Genetics (2016)
Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.
Authors: Heinz Ludwig, Zdenek Adam, Roman Hajek, Richard Greil, Felix Keil, Niklas Zojer, Josef Thaler, Heinz Gisslinger, Alois Lang
Journal: Blood (2007)
TCT-477 Long-term risk of stent thrombosis and restenosis after treatment with drug-eluting stents: A report from SCAAR
Authors: Christian Dworeck, Oscar Angeras, Inger Haraldsson, Dan Ioanes, Jacob Odenstedt, Petur Petursson, Lotta Robertsson, Jason Stewart, Sebastian Volz, Per Albertsson, Truls Råmunddal, Elmir Omerovic
Journal: Journal of the American College of Cardiology (2016)
KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis
Authors: Peng Yuan, Xiao-Hong He, Ye-Fei Rong, Jing Cao, Yong Li, Yun-Ping Hu, Yingbin Liu, Dangsheng Li, Wenhui Lou, Mo-Fang Liu
Journal: Cancer Research (2016)

Abstract KRAS activation occurring in more than 90% of pancreatic ductal adenocarcinomas (PDAC) drives progression and metastasis, but the underlying mechanisms involved in these processes are still poorly understood. Here, we show how KRAS acts through inflammatory NF-κB signaling to activate the transcription factor YY1, which represses expression of the tumor suppressor gene miR-489. In PDAC cells, repression of miR-489 by KRAS signaling inhibited migration and metastasis by targeting the extracellular matrix factors ADAM9 and MMP7. miR-489 downregulation elevated levels of ADAM9 and MMP7, thereby enhancing the migration and metastasis of PDAC cells. Together, our results establish a pivotal mechanism of PDAC metastasis and suggest miR-489 as a candidate therapeutic target for their attack. Cancer Res; 77(1); 100–11. ©2016 AACR.
Pulmonary Artery Sarcoma
Authors: Ramiro Fernandez, Daphne Edgren, Ankit Bharat
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Figure 1.Chest radiograph revealed a right hilar mass (A), which on contrast-enhanced computed tomography was found to be a large intravascular tumor occluding the right main pulmonary artery with extension into the lumen of the main and left pulmonary arteries (B).A dynamic magnetic resonance image demonstrated the tumor within the main pulmonary artery but without mural invasion (C).Tumor within the main pulmonary artery as visualized intraoperatively after pulmonary arteriotomy (D).Gross histology demonstrated involvement of superior, middle, and inferior lobes (E) with tumor completely occluding the right pulmonary artery lumen (F).
Transcaval Access and Closure for Transcatheter Aortic Valve Replacement
Authors: Adam B. Greenbaum, Vasilis C. Babaliaros, Marcus Y. Chen, Annette M. Stine, Toby Rogers, William W. O’Neill, Gaetano Paone, Vinod H. Thourani, Kamran I. Muhammad, Robert A. Leonardi, Stephen Ramee, James F. Troendle, Robert J. Lederman
Journal: Journal of the American College of Cardiology (2016)
Estimation of the Prevalence of Pulmonary Artery Hypertension in a Large Group of β-Thalassemia Patients Using Right Heart Catheterization
Authors: Giorgio Derchi, Renzo Galanello, Patrizio Bina, Maria D Cappellini, Antonio Piga, Maria-Eliana Lai, Antonella Quarta, Gavino Casu, Silverio Perrotta, Khaled M Musallam, Gian Luca Forni
Journal: Blood (2012)
TCT-332 Predictors of midterm restenosis in angulated lesions after drug-eluting stent implantation
Authors: Kazuki Matsushita, Kazushige Kadota, Yusuke Hyodo, Suguru Otsuru, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto
Journal: Journal of the American College of Cardiology (2016)
Gestalt-like representations hijack Chunk-and-Pass processing
Authors: Magda L Dumitru
Journal: Behavioral and Brain Sciences (2016)

Abstract Christiansen &amp; Chater (C&amp;C) make two related and somewhat contradictory claims, namely that the ever abstract language representations built during Chunk-and-Pass processing allow for ever greater interference from extra-linguistic information, and that it is nevertheless the language system that re-codes incoming information into abstract representations. I analyse these claims and discuss evidence suggesting that Gestalt-like representations hijack Chunk-and-Pass processing.
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine
Authors: Scott W. Powers, Christopher S. Coffey, Leigh A. Chamberlin, Dixie J. Ecklund, Elizabeth A. Klingner, Jon W. Yankey, Leslie L. Korbee, Linda L. Porter, Andrew D. Hershey
Journal: New England Journal of Medicine (2016)

Which medication, if any, to use to prevent the headache of pediatric migraine has not been established.We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescents 8 to 17 years of age with migraine. Patients were randomly assigned in a 2:2:1 ratio to receive one of the medications or placebo. The primary outcome was a relative reduction of 50% or more in the number of headache days in the comparison of the 28-day baseline period with the last 28 days of a 24-week trial. Secondary outcomes were headache-related disability, headache days, number of trial completers, and serious adverse events that emerged during treatment.A total of 361 patients underwent randomization, and 328 were included in the primary efficacy analysis (132 in the amitriptyline group, 130 in the topiramate group, and 66 in the placebo group). The trial was concluded early for futility after a planned interim analysis. There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group (amitriptyline vs. placebo, P=0.26; topiramate vs. placebo, P=0.48; amitriptyline vs. topiramate, P=0.49). There were also no significant between-group differences in headache-related disability, headache days, or the percentage of patients who completed the 24-week treatment period. Patients who received amitriptyline or topiramate had higher rates of several adverse events than those receiving placebo, including fatigue (30% vs. 14%) and dry mouth (25% vs. 12%) in the amitriptyline group and paresthesia (31% vs. 8%) and weight loss (8% vs. 0%) in the topiramate group. Three patients in the amitriptyline group had serious adverse events of altered mood, and one patient in the topiramate group had a suicide attempt.There were no significant differences in reduction in headache frequency or headache-related disability in childhood and adolescent migraine with amitriptyline, topiramate, or placebo over a period of 24 weeks. The active drugs were associated with higher rates of adverse events. (Funded by the National Institutes of Health; CHAMP ClinicalTrials.gov number, NCT01581281 ).
TCT-245 Association of intraoperative transit time flow after grafting and invasive coronary flow and pressure measurements before coronary artery bypass surgery.
Authors: Anne Langhoff Thuesen, Lars Riber, Poul Erik Mortensen, Akhmadjon Irmukhamedov, Peter Appel Pallesen, Knud Nørregaard Hansen, Julia Ellert, Anders Junker, Katsuomi Iwakura, Lisette Okkels Jensen
Journal: Journal of the American College of Cardiology (2016)
TCT-337 Prognostic value of high-sensitivity cardiac troponin T and gender differences in patients undergoing elective percutaneous coronary intervention
Authors: Yukinori Harada, Jonathan Michel, Wolfgang Koenig, Tobias Rheude, Roisin Colleran, Daniele Giacoppo, Jens Wiebe, Adnan Kastrati, Robert Byrne
Journal: Journal of the American College of Cardiology (2016)